

Prism Medico & Pharmacy Limited

CIN: L51109PB2002PLC047444

D-118, INDUSTRIAL AREA,
PHASE VII, MOHALI-160055
Telephone no – 0172-5020762
Email Id – investorgrivancewmcl@gmail.com

Date: 14/08/2018

To, Department of Corporate Services, BSE Limited P.J. Towers, Dalal Street, Mumbai – 400 001. Scip Code: 512217	To, Listing Department, Metropolitan Stock Exchange of India Ltd. (MSE) Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098, India. ISIN : INE730E01016
---	---

Subject: Outcome of Board meeting held on Tuesday, 14th August, 2018

Starting Time: 11.00 a.m. Concluding Time: 12.30 p.m.

Dear Sir/Madam

Pursuant to the provisions of Regulations 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Tuesday, 14th August, 2018:


1. Consider and Approved and taken on records the Un-Audited Financial Results (Standalone and Consolidated) along with Limited Review Report for the quarter ended on June 30, 2018 as recommended by the Audit Committee.
Further, we hereby enclose the following:
 - a. Un-Audited Financial Results for the quarter ended on June 30, 2018.
 - b. Limited Review Report from the Statutory Auditor of the Company
2. Considered and approved the date of Annual General Meeting and the same shall to be held on Thursday, 27th September, 2018.
3. Considered the issue and allotment, subject to the approval of Shareholders, equity shares on preferential basis as per SEBI (ICDR) Regulations.

4. Considered the increase of Authorized Share Capital from 10,00,00,000 to 20,00,00,000, subject to the approval of Shareholders in Annual General Meeting of the company.
5. Considered the change in main objects of the Company to reflect the company more dominantly subject to the approval of Shareholders in Annual General Meeting of the company.
6. Considered and approved the name change of the Company from "Prism Medico and Pharmacy Limited" to "Richmond Agrotech Limited" subject to the approval of the Registrar of Companies, Punjab & Chandigarh and the approval of the members

You are requested to take the same on record and acknowledge receipt.

Thanking You,

For, **PRISM MEDICO AND PHARMACY LIMITED**
For **PRISM MEDICO AND PHARMACY LIMITED**



Gursimran Singh AUTHORIZED SIGNATORY
DIRECTOR
DIN: 02209675



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report on Consolidated Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Consolidated Un-Audited Financial Result of M/s. Prism Medico And Pharmacy Ltd having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th June 2018 ("the Statement") and its subsidiary naming M/s Healthy Biosciences Private Limited attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The Consolidated Statement includes the financial results of the following entity naming M/s Healthy Biosciences Private Limited.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Consolidated Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any martial misstatement.

Date : 10-August-2018
Place: Mohali

For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N


CA Suprit Kaur
Partner
M.No 424986




PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR/ QUARTER ENDED 30TH JUNE, 2018 (IN LAKHS)


PARTICULARS	Quarter Ended			Year Ended	
	30.06.2018	31.03.2018	30.06.2017	31.03.2018	31.03.2017
REVENUE FROM OPERATIONS	576.72	35.99	1210.48	2280.22	527.49
OTHER INCOME	0.90	2.94	0.87	4.26	7.31
TOTAL REVENUE	577.62	38.93	1211.35	2284.48	534.80
EXPENSES:					
PURCHASE OF STOCK-IN-TRADE	441.90	33.37	847.37	1948.16	86.35
CHANGE IN INVENTORIES	85.59	184.93	106.51	179.84	-70.01
EMPLOYEE BENEFIT EXPENSES	3.39	9.26	4.70	21.06	28.47
FINANCE COSTS	0.94	7.14	7.74	28.87	13.79
COST OF MATERIAL CONSUMED		-192.35	151.93	0.00	397.04
PAYMENT TO BSE	3.05	2.88	0.00	2.88	2.30
DEPRECIATION	9.47	12.92	8.23	44.65	20.62
OTHER EXPENSES	1.36	16.00	17.23	52.21	77.48
TOTAL EXPENSES	545.69	74.15	1143.71	2277.66	556.03
PROFIT BEFORE TAX	31.93	-35.22	67.64	6.81	-21.23
TAX EXPENSE:					
(1)CURRENT TAX	0.00	1.30	0.00	1.30	0.25
(2)DEFERRED TAX	0	7.22	0.00	7.22	0.60
(3) MAT Credit	0	1.30	0.00	1.30	0.25
PROFIT(LOSS) FOR THE PERIOD	31.93	-42.44	67.64	-0.41	-21.82
OTHER COMPREHENSIVE INCOME, NET					
A) i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
B) i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
Total Other Comprehensive income, Net of Income Tax	0.00	0.00	0.00	0.00	0.00
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD					
PAID UP EQUITY SHARE CAPITAL: (FACE VALUE RS. 10 EACH)	606.34	606.34	606.34	606.34	606.34
EARNINGS PER EQUITY SHARE					
(1)BASIC	0.53	-0.70	1.12	-0.01	-0.36
(2)DILUTED	0.53	-0.70	1.12	-0.01	-0.36

For PRISM MEDICO AND PHARMACY LTD.

 AUTHORISED SIGNATORY

NOTES:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14TH AUGUST, 2018.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

**For and on behalf of Board of
Prism medico and Pharmacy Limited**
For PRISM MEDICO AND PHARMACY LTD.



Gursimran Singh AUTHORIZED SIGNATORY

Director

DIN: 02209675

Place : Mohali

Date : 10.08.2018

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLCO47444

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH JUNE, 2018

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS ON
	30TH JUNE 2018	31st MARCH 2018

I. EQUITY AND LIABILITIES

(1) SHAREHOLDER'S FUND

(A) SHARE CAPITAL	606.34	606.34
(B) RESERVES AND SURPLUS	712.77	680.84

(2) NON CURRENT LIABILITIES

(A) DEFERRED TAX LIABILITIES (NET)	7.49	7.49
(B) LONG TERM BORROWINGS	54.81	91.54
(C) OTHER NON-CURRENT LIABILITIES		2.50

(3) CURRENT LIABILITIES

(A) SHORT TERM BORROWINGS	0.02	125.16
(B) TRADE PAYABLE	134.20	53.06
(C) CURRENT LIABILITIES	5.78	11.72
(D) SHORT TERM PROVISIONS	1.30	1.30

TOTAL EQUITY & LIABILITIES	1,522.71	1,579.95
---------------------------------------	-----------------	-----------------

II. ASSETS

(1) NON CURRENT ASSETS

(A) FIXED ASSETS		
(i) TANGIBLE ASSETS	921.18	930.65
(B) NON CURRENT INVESTMENTS	260.72	260.72
(C) LONG TERM LOANS & ADVANCES	78.29	2.30
(D) OTHER NON CURRENT ASSETS		-

(2) CURRENT ASSETS

(A) INVENTORIES	63.51	149.10
(B) TRADE RECEIVABLES	140.91	-
(C) CASH AND CASH EQUIVALENTS	33.40	135.82
(D) SHORT TERM LOANS AND ADVANCES	21.60	96.01
(E) OTHER CURRENT ASSETS	3.11	5.36

TOTAL-ASSETS	1,522.71	1,579.95
---------------------	-----------------	-----------------

SIGNIFICANT ACCOUNTING POLICIES OTHER INFORMATION


(The note nos 1 to 19 are integrated part of these financial statements)
As per our report of even date attached

Place : Mohali

Date : 10.08.2018

**For and on behalf of Board of
Prism Medico and Pharmacy Limited**

For PRISM MEDICO AND PHARMACY LIMITED



Gursimran Singh
AUTHORISED SIGNATORY

Director

DIN: 02209675



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report

Review Report To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the accompanying statement of Un-Audited Financial Result of M/s. **Prism Medico And Pharmacy Ltd** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th June, 2018 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-Audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any martial misstatement.

Date: 10-August-2018
Place: Mohali

For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N


CA Suprit Kaur
Partner
M.No 424986




PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLCO47444

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR/ QUARTER ENDED 30TH JUNE, 2018 (IN LAKHS)

PARTICULARS	Quarter Ended			Year Ended	
	30.06.2018	31.03.2018	30.06.2017	31.03.2018	31.03.2017
REVENUE FROM OPERATIONS	571.42	545.44	514.79	2095.81	8.70
OTHER INCOME	0.00	0.00	0.00	0.00	6.69
TOTAL REVENUE	571.42	545.44	514.79	2095.81	15.39
EXPENSES:					
PURCHASE OF STOCK-IN-TRADE	456.35	541.39	411.58	2072.70	79.00
CHANGE IN INVENTORIES	85.59	23.05	0.00	-9.55	-79.00
EMPLOYEE BENEFIT EXPENSES	3.39	7.39	0.35	9.54	0.75
FINANCE COSTS	0.00	0.01	0.00	0.02	0.01
COST OF MATERIAL CONSUMED	0.00	0.00	0.00	0.00	0.00
PAYMENT TO BSE	3.05	1.37	2.88	2.88	2.30
DEPRECIATION	0.67	2.95	1.49	4.46	1.56
OTHER EXPENSES	0.87	0.76	1.27	11.10	33.31
TOTAL EXPENSES	549.91	576.91	417.56	2091.15	37.93
PROFIT BEFORE TAX	21.50	-31.47	97.23	4.66	-22.54
TAX EXPENSE:					
(1) CURRENT TAX	0.00	0.89	0.00	0.89	0.00
(2) DEFERRED TAX	0.00	6.56	0.00	6.56	0.19
(3) MAT Credit	0.00	0.89	0.00	0.89	0.00
PROFIT (LOSS) FOR THE PERIOD	21.50	-38.03	97.23	-1.89	-22.73
OTHER COMPREHENSIVE INCOME, NET OF INCOME TAX					
A) i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
B) i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
TOTAL OTHER COMPREHENSIVE INCOME, NET OF INCOME TAX	-	-	-	-	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD					
PAYED UP EQUITY SHARE CAPITAL: (FACE VALUE RS. 10 EACH)	606.34	606.34	606.34	606.34	606.34
EARNINGS PER EQUITY SHARE	0.35	-0.63	1.60	-0.03	-0.37
	0.35	-0.63	1.60	-0.03	-0.37

FOR PRISM MEDICO AND PHARMACY LIMITED


AUTHORISED SIGNATORY

NOTES:

NOTES:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th August, 2018.


2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.

3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

Place : Mohali
Date : 10.08.2018

**For and on behalf of Board of
Prism Medico and Pharmacy
Limited**

FOR PRISM MEDICO AND PHARMACY LIMITED



Gursimran Singh AUTHORIZED SIGNATORY

Director

DIN: 02209675

PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH JUNE, 2018 (FIGURES IN LAKHS)

STANDALONE STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS AT
	30-06-2018	31st MARCH 2018
I. EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	606.34	606.34
(B) RESERVES AND SURPLUS	693.30	671.80
(2) NON CURRENT LIABILITIES		
(A) DEFFERED TAX LIABILITIES (NET)	6.74	6.74
(B) LONG TERM BORROWINGS		
(2) CURRENT LIABILITIES		
(A) SHORT TERM BORROWINGS		-
(B) TRADE PAYABLE		-
(C) CURRENT LIABILITIES	41.85	7.89
(D) SHORT TERM PROVISIONS	0.89	0.89
TOTAL EQUITY & LIABILITIES	1,349.12	1,293.67


II. ASSETS

(1) NON CURRENT ASSETS		
(A) FIXED ASSETS		
(i) TANGIBLE ASSETS	10.54	11.21
(B) NON CURRENT INVESTMENTS	1,125.00	1,125.00
(C) LONG TERM LOANS & ADVANCES		
(D) OTHER NON CURRENT ASSETS		
(2) CURRENT ASSETS		
(A) INVENTORIES	2.96	88.55
(B) TRADE RECEIVABLES	140.91	
(C) CASH AND CASH EQUIVALENTS	4.09	4.02
(D) SHORT TERM LOANS AND ADVANCES	64.73	64.01
(E) OTHER CURRENT ASSETS	0.89	0.89
TOTAL-ASSETS	1,349.12	1,293.67

SIGNIFICANT ACCOUNTING POLICIES OTHER INFORMATION

(The note nos 1 to 19 are integrated part of these financial statements)
As per our report of even date attached

Place : Mohali
Date : 10.08.2018

**For and on behalf of Board of
Prism medico and Pharmacy Limited**
For PRISM MEDICO AND PHARMACY LIMITED

Gursimran Singh
AUTHORISED SIGNATORY
Director
DIN: 02209675